| Gene symbol | TNFRSF17 | Synonyms | BCM, BCMA, CD269, TNFRSF13A | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p13.13 | dbXrefs | |
| Description | TNF receptor superfamily member 17 | ||||
| Gene symbol | CD19 | Synonyms | B4, CVID3 | Type of gene | protein-coding |
| Chromosome | 16 | Map location | 16p11.2 | dbXrefs | |
| Description | CD19 molecule | ||||
| GTO ID | GTC3931 |
| Trial ID | NCT06485232 |
| Disease | Neuromyelitis Optica Spectrum Disorder | Generalized Myasthenia Gravis | Multiple Sclerosis | Chronic Inflammatory Demyelinating Polyradiculoneuropathy |
| Altered gene | BCMA|CD19 |
| Therapeutic/Target gene | Target gene |
| Therapy | CAR-T cell |
| Treatment | BCMA/CD19 CAR-T cells |
| Phase | Early_Phase1 |
| Recruitment status | Not Recruiting |
| Title | An Exploratory Study on the Safety and Efficacy of Universal CAR-T Cells Targeting BCMA and CD19 in the Treatment of Refractory Autoimmune Diseases of the Nervous System |
| Year | 2024 |
| Country | China |
| Company sponsor | Xuanwu Hospital, Beijing |
| Other ID(s) | 2024-BRL-302-02 |
| Cohort 1 | |||||||
|
|||||||